Fallopian Tube Cancer Clinical Trial
— UP-NEXTOfficial title:
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)
Verified date | October 2023 |
Source | Mersana Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC), including fallopian tube and primary peritoneal cancer, expressing high levels of NaPi2b.
Status | Terminated |
Enrollment | 20 |
Est. completion date | September 29, 2023 |
Est. primary completion date | September 29, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Participant must have a histological diagnosis of high grade serous ovarian cancer, which includes fallopian tube and primary peritoneal cancer, that is metastatic or recurrent. 2. Participant must have platinum-sensitive recurrent disease, defined as having achieved either a partial or complete response to 4 or more cycles in their penultimate platinum- containing regimen and their disease progressing more than 6 months after completion of the last dose of platinum containing therapy in the penultimate regimen. 3. Participant must have had 4 to 8 cycles of platinum-based chemotherapy in 2nd to 4th line setting in their most recent treatment regimen as defined below: 1. Platinum-based chemotherapy regimens allowed immediately preceding enrollment to the study: carboplatin or cisplatin ±: paclitaxel, docetaxel, pegylated liposomal doxorubicin or gemcitabine. 2. Participant must receive first study treatment infusion between 4 and 12 weeks after completing final dose of platinum in the most recent platinum-based regimen. 4. Participant must have had as their best response to last line of treatment one of the following: No Evidence of Disease (NED); Complete Response (CR); Partial Response (PR); OR Stable Disease (SD) 5. Participants with NED, CR, or PR as their best response to most recent line of treatment and who have not received treatment with a prior PARP inhibitor must have definitive BRCA1 and BRCA2 testing results that demonstrate no evidence of a deleterious BRCA1 or BRCA2 mutation. Somatic BRCA mutation testing is required for participants who are classified as not having a deleterious mutation by germline testing alone. 6. Participant must provide either a tumor tissue block or fresh cut slides for measurement of NaPi2b expression by a central laboratory. If sufficient archival tumor tissue is not available, then a tumor tissue block or slides must be obtained from a fresh biopsy and provided to the central laboratory. Confirmation of a NaPi2b-H/positive tumor by the central laboratory is required prior to randomization. Exclusion Criteria: 1. Participant has received prior treatment with mirvetuximab soravtansine or another ADC containing an auristatin or maytansinoid payload. 2. Participant has received bevacizumab in combination with last platinum-based regiment or plans to receive maintenance therapy outside the study intervention. 3. Participant has clinical signs or symptoms of gastrointestinal obstruction and/or requirement for parenteral hydration or nutrition. 4. Participant has ascites or pleural effusion managed with therapeutic paracentesis or thoracentesis within 28 days prior to signing the principal study consent form. 5. Participant has history of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver disease. Testing beyond laboratory studies otherwise defined in the eligibility criteria, to diagnose potentially clinically significant liver disease based on risk factors such as hepatic steatosis or history of excessive alcohol intake, will be based on clinical judgement of the investigator. 6. Participant has history of or suspected pneumonitis or interstitial lung disease. 7. Participant has untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis, or carcinomatous meningitis. |
Country | Name | City | State |
---|---|---|---|
Australia | Epworth Richmond | Richmond | Victoria |
Canada | Sherbrooke University Hospital Centre | Quebec | Sherbrooke |
United States | Southwest Women's Oncology | Albuquerque | New Mexico |
United States | University of New Mexico Cancer Center | Albuquerque | New Mexico |
United States | Texas Oncology P.A. - Austin | Austin | Texas |
United States | Texas Oncology - DFWW | Bedford | Texas |
United States | Billings Clinic | Billings | Montana |
United States | University of Chicago Medical Center | Chicago | Illinois |
United States | University Hospitals Cleveland Medical Center, Seidman Cancer Center | Cleveland | Ohio |
United States | Karmanos Cancer Institute - Detroit | Detroit | Michigan |
United States | Willamette Valley Cancer Institute and Research Center | Eugene | Oregon |
United States | Kettering Health Cancer Center | Kettering | Ohio |
United States | Women's Cancer Center of Nevada | Las Vegas | Nevada |
United States | University of California Los Angeles, Gynecologic Oncology Clinic | Los Angeles | California |
United States | University of Wisconsin Clinical Science Center | Madison | Wisconsin |
United States | Froedtert Hospital and the Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Stephenson Cancer Center | Oklahoma City | Oklahoma |
United States | Methodist Hospital | Omaha | Nebraska |
United States | University of California, Irvine Medical Center | Orange | California |
United States | HonorHealth Research Institute - HonorHealth VGPCC Biltmore | Phoenix | Arizona |
United States | Legacy Good Samaritan Medical Center - Legacy Medical Group - Gynecologic Oncology | Portland | Oregon |
United States | Center of Hope | Reno | Nevada |
United States | VCU Massey Cancer Center | Richmond | Virginia |
United States | Sarasota Memorial Hospital | Sarasota | Florida |
United States | WK Physicians | Shreveport | Louisiana |
United States | Avera McKennan d/b/a Avera Research Institute | Sioux Falls | South Dakota |
United States | Sanford Gynecologic Oncology | Sioux Falls | South Dakota |
United States | The University of Arizona Cancer Center | Tucson | Arizona |
United States | Texas Oncology - Tyler | Tyler | Texas |
United States | Asplundh Cancer Pavilion | Willow Grove | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Mersana Therapeutics | European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation |
United States, Australia, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | PFS is defined as the time from randomization to the earliest date of progressive disease as assessed by BICR per RECIST Version 1.1 or death due to any cause. | Up to 12 months after the last dose for the last participant. | |
Secondary | Overall Survival (OS) | OS is defined as the time from randomization to the date of death due to any cause. | Up to an average of 4 years. Follow up assessments for survival data will continue every 90 days following completion of treatment. | |
Secondary | Progression-free Survival (PFS) as assessed by Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | PFS is defined as the time from randomization to the earliest date of progressive disease as assessed by Investigator per RECIST Version 1.1 or death due to any cause. | Up to 12 months after the last dose for the last participant. | |
Secondary | Adverse events (AEs) based on NCI CTCAE Version 5.0 | Incidence and toxicity grade of AEs. | Up to 60 days past last dose | |
Secondary | Changes in Eastern Cooperative Oncology Group (ECOG) performance status | Assessment of ECOG performance status using ECOG performance scale. | Up to 60 days past last dose. | |
Secondary | Objective Response Rate (ORR) as assessed by Investigator using RECIST Version 1.1 | ORR is the percentage of patients achieving a confirmed complete response (CR) or partial response (PR) as assessed by Investigator per RECIST Version 1.1. | Up to 12 months after the last dose for the last participant. | |
Secondary | Number of participants using concomitant medications | Assessment of concomitant medication usage. | Up to 60 days past last dose. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03393884 -
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
|
Phase 1/Phase 2 | |
Completed |
NCT04546373 -
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
|
||
Active, not recruiting |
NCT05456685 -
IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer
|
Phase 2 | |
Completed |
NCT01442051 -
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer
|
N/A | |
Completed |
NCT02928549 -
Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study
|
||
Active, not recruiting |
NCT03648489 -
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
|
Phase 2 | |
Not yet recruiting |
NCT04983550 -
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
|
Phase 2 | |
Completed |
NCT02480374 -
Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer
|
Phase 1 | |
Completed |
NCT01899599 -
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT01610206 -
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
|
Phase 2 | |
Completed |
NCT03480750 -
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01219777 -
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
|
Phase 1 | |
Completed |
NCT01031381 -
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
|
Phase 2 | |
Completed |
NCT00959582 -
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
|
Phase 1 | |
Suspended |
NCT00753480 -
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
|
Phase 1 | |
Completed |
NCT00768144 -
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
|
Phase 2 | |
Completed |
NCT00801320 -
Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer
|
N/A | |
Completed |
NCT00702299 -
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT02349958 -
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
|
Phase 2 | |
Completed |
NCT00390234 -
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
|
Phase 2 |